EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D

Prerna Arora iD, Lu Zhang iD, Inga Nehlmeier, Amy Kempf, Luise Graichen, Eike Kreitz, Anzhalika Sidarovich, Cheila Rocha, Sabine Gärtner, Michael Winkler, Sebastian Schulz, Hans-Martin Jäck und 2 weitere

Journal of Virology · 2025

DOI: 10.1128/jvi.01230-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Prerna Arora und 13 weiteren Autor:innen. Beteiligte Einrichtung: Infection Biology Unit, German Primate Centre - Leibniz Institute for Primate Research, Göttingen, Germany. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, Lectins, C-Type, Receptors, Cell Surface. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EC | Horizon Europe | | HORIZON EUROPE Health (Health), Niedersächsisches Ministerium für Wissenschaft und Kultur (MWK), Deutsche Forschungsgemeinschaft (DFG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The naturally occurring mutation E484D in the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can render viral entry ACE2 independent and imdevimab resistant. Here, we investigated whether the cellular proteins ASGR1, DC-SIGN, and TMEM106B, which interact with the viral S protein, can contribute to these processes. Employing S protein-pseudotyped particles, we found that expression of ASGR1 or DC-SIGN jointly with TMEM106B allowed for robust entry of mutant E484D into otherwise non-susceptible cells, while this effect was not observed upon separate expression of the single proteins and upon infection with SARS-CoV-2 wild type (WT). Furthermore, expression of ASGR1 or DC-SIGN conferred ACE2 independence and imdevimab resistance to entry of mutant E484D but not WT, and entry under those conditions was dependent on endogenous TMEM106B. These results suggest that engagement of certain cellular lectins can direct SARS-CoV-2 mutant E484D to an ACE2-independent, TMEM106B-dependent entry pathway that is not inhibited by imdevimab. IMPORTANCE The interaction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein with the ACE2 receptor determines the viral cell tropism and is the key target of the neutralizing antibody response. Here, we show that SARS-CoV-2 with a single, naturally occurring mutation in the spike protein, E484D, can use the cellular lectins ASGR1 and DC-SIGN in conjunction with TMEM106B for ACE2-independent entry and evasion of therapeutic antibodies. These results suggest that engagement of cellular lectins might modulate target cell choice of SARS-CoV-2 and might allow evasion of certain neutralizing antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2Lectins, C-TypeReceptors, Cell SurfaceAngiotensin-Converting Enzyme 2Cell Adhesion MoleculesMembrane ProteinsNerve Tissue ProteinsHumansVirus InternalizationMutationCOVID-19HEK293 CellsCOVID-19 Drug TreatmentAntiviral AgentsDrug Resistance, ViralDC-Specific ICAM-3 Grabbing Nonintegrin

Stichwörter der Autor:innen

SARS-CoV-2entrylectinneutralizationspike

Substanzen

Spike Glycoprotein, CoronavirusLectins, C-TypeReceptors, Cell SurfaceAngiotensin-Converting Enzyme 2Cell Adhesion MoleculesMembrane ProteinsNerve Tissue ProteinsAntiviral AgentsDC-Specific ICAM-3 Grabbing Nonintegrinspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Infection Biology Unit, German Primate Centre - Leibniz Institute for Primate Research, Göttingen, Germany.
  • Faculty of Biology and Psychology, Georg-August-University Göttingen, Göttingen, Germany.
  • Division of Molecular Immunology, Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Prerna Arora, Lu Zhang, Stefan Pöhlmann

Förderung

  • EC | Horizon Europe | | HORIZON EUROPE Health (Health)
  • Niedersächsisches Ministerium für Wissenschaft und Kultur (MWK)
  • Deutsche Forschungsgemeinschaft (DFG)
  • Bundesministerium für Bildung und Forschung (BMBF)
  • Bayerische Forschungsstiftung (Bavarian Research Foundation)
  • EC | Horizon Europe | 全球挑戰和歐洲工業競爭力 | HORIZON EUROPE Health

Zitieren

APA

Arora, P., Zhang, L., Nehlmeier, I., Kempf, A., Graichen, L., Kreitz, E., Sidarovich, A., Rocha, C., Gärtner, S., Winkler, M., Schulz, S., Jäck, H. M., Hoffmann, M., & Pöhlmann, S. (2025). Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D. Journal of Virology. https://doi.org/10.1128/jvi.01230-24

Vancouver

Arora P, Zhang L, Nehlmeier I, Kempf A, Graichen L, Kreitz E, et al. Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D. Journal of Virology. 2025. doi:10.1128/jvi.01230-24

BibTeX
@article{Arora2025,
  author = {Arora, Prerna and Zhang, Lu and Nehlmeier, Inga and Kempf, Amy and Graichen, Luise and Kreitz, Eike and Sidarovich, Anzhalika and Rocha, Cheila and Gärtner, Sabine and Winkler, Michael and Schulz, Sebastian and Jäck, Hans-Martin and Hoffmann, Markus and Pöhlmann, Stefan},
  title = {Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.01230-24}
}
Kostenlos starten →